BioNTech SE at JPMorgan Healthcare Conference Transcript
Good morning, everyone, and welcome to the third day of the JPMorgan Healthcare Conference. My name is Matthew Holt, and I'm a member on the biotech equity research team here at JPMorgan. It's my pleasure to introduce our next presenting company, BioNTech. And presenting today for BioNTech will be CEO and Co-Founder, Ugur Sahin. And please note that following Ugur's presentation, there's a breakout room in the Yorkshire room across the hall. So with that, I'll hand it over to Ugur.
Yes. Good morning. It's a pleasure to have the opportunity to present here. I'm Ugur Sahin. I'm Co-Founder and CEO of BioNTech, and I would like to directly start with our goals. We have -- our goal is to build a 21st Century individualized cancer immunotherapy company. And to this end, we are developing next-generation immunotherapies for cancer and other diseases. So our approach is technology agnostic. We are exploiting novel-targets
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |